Literature DB >> 21885386

Titrated oxygen requirement and prognostication in idiopathic pulmonary fibrosis.

J L Hook1, S M Arcasoy, D Zemmel, M N Bartels, S M Kawut, D J Lederer.   

Abstract

The supplemental oxygen flow rate is a common bedside measure of gas exchange impairment. We aimed to determine whether a titrated oxygen requirement (TOR) predicted mortality in idiopathic pulmonary fibrosis (IPF). We examined 104 adults with IPF enrolled in a prospective cohort study and a validation cohort of 151 adults with a variety of interstitial lung diseases (ILDs). The TOR was defined as the lowest oxygen flow rate required to maintain an oxyhaemoglobin saturation of 96% while standing. Cox proportional hazards models and time-dependent receiver operating characteristic curves were used to examine survival time. A higher TOR was associated with a greater mortality rate independent of forced vital capacity and 6-min walk test results in IPF (adjusted hazard ratio (per 1 L·min(-1)) 1.16, 95% CI 1.06-1.27). The TOR was at least as accurate as pulmonary function and 6-min walk testing at predicting 1-yr mortality. Findings were similar in other ILDs. The TOR is a simple, inexpensive bedside measurement that aids prognostication in IPF.

Entities:  

Mesh:

Year:  2011        PMID: 21885386      PMCID: PMC3236811          DOI: 10.1183/09031936.00108111

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  25 in total

Review 1.  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

2.  ATS statement: guidelines for the six-minute walk test.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-07-01       Impact factor: 21.405

3.  Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.

Authors:  Harold R Collard; Talmadge E King; Becki Bucher Bartelson; Jason S Vourlekis; Marvin I Schwarz; Kevin K Brown
Journal:  Am J Respir Crit Care Med       Date:  2003-05-28       Impact factor: 21.405

4.  Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation.

Authors:  N Mogulkoc; M H Brutsche; P W Bishop; S M Greaves; A W Horrocks; J J Egan
Journal:  Am J Respir Crit Care Med       Date:  2001-07-01       Impact factor: 21.405

Review 5.  Idiopathic pulmonary fibrosis.

Authors:  T J Gross; G W Hunninghake
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

6.  Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model.

Authors:  T E King; J A Tooze; M I Schwarz; K R Brown; R M Cherniack
Journal:  Am J Respir Crit Care Med       Date:  2001-10-01       Impact factor: 21.405

7.  Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality.

Authors:  T E King; M I Schwarz; K Brown; J A Tooze; T V Colby; J A Waldron; A Flint; W Thurlbeck; R M Cherniack
Journal:  Am J Respir Crit Care Med       Date:  2001-09-15       Impact factor: 21.405

Review 8.  Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy.

Authors:  M Selman; T E King; A Pardo
Journal:  Ann Intern Med       Date:  2001-01-16       Impact factor: 25.391

9.  Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia.

Authors:  Kevin R Flaherty; Jeanette A Mumford; Susan Murray; Ella A Kazerooni; Barry H Gross; Thomas V Colby; William D Travis; Andrew Flint; Galen B Toews; Joseph P Lynch; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2003-05-28       Impact factor: 21.405

10.  Heart rate recovery after 6-min walk test predicts survival in patients with idiopathic pulmonary fibrosis.

Authors:  Jeffrey J Swigris; Jeff Swick; Frederick S Wamboldt; David Sprunger; Roland du Bois; Aryeh Fischer; Gregory P Cosgrove; Stephen K Frankel; Evans R Fernandez-Perez; Dolly Kervitsky; Kevin K Brown
Journal:  Chest       Date:  2009-04-24       Impact factor: 9.410

View more
  6 in total

Review 1.  Idiopathic Pulmonary Fibrosis: Best Practice in Monitoring and Managing a Relentless Fibrotic Disease.

Authors:  Wim A Wuyts; Marlies Wijsenbeek; Benjamin Bondue; Demosthenes Bouros; Paul Bresser; Carlos Robalo Cordeiro; Ole Hilberg; Jesper Magnusson; Effrosyni D Manali; António Morais; Spyridon Papiris; Saher Shaker; Marcel Veltkamp; Elisabeth Bendstrup
Journal:  Respiration       Date:  2019-12-12       Impact factor: 3.580

2.  Determinants of 6-minute walk distance in patients with idiopathic pulmonary fibrosis undergoing lung transplant evaluation.

Authors:  Mary K Porteous; Belinda N Rivera-Lebron; Maryl Kreider; James Lee; Steven M Kawut
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

Review 3.  Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 2. Idiopathic Pulmonary Fibrosis.

Authors:  Sang Hoon Lee; Yoomi Yeo; Tae Hyung Kim; Hong Lyeol Lee; Jin Hwa Lee; Yong Bum Park; Jong Sun Park; Yee Hyung Kim; Jin Woo Song; Byung Woo Jhun; Hyun Jung Kim; Jinkyeong Park; Soo Taek Uh; Young Whan Kim; Dong Soon Kim; Moo Suk Park
Journal:  Tuberc Respir Dis (Seoul)       Date:  2019-02-28

Review 4.  Management of Chronic Respiratory Failure in Interstitial Lung Diseases: Overview and Clinical Insights.

Authors:  Paola Faverio; Federica De Giacomi; Giulia Bonaiti; Anna Stainer; Luca Sardella; Giulia Pellegrino; Giuseppe Francesco Sferrazza Papa; Francesco Bini; Bruno Dino Bodini; Mauro Carone; Sara Annoni; Grazia Messinesi; Alberto Pesci
Journal:  Int J Med Sci       Date:  2019-06-10       Impact factor: 3.738

5.  Features and predictive value of 6-min walk test outcomes in interstitial lung disease: an observation study using wearable monitors.

Authors:  Jiaying Li; Xiaoyan Li; Miaozhen Deng; Xinyin Liang; Huiqun Wei; Xiaobing Wu
Journal:  BMJ Open       Date:  2022-06-15       Impact factor: 3.006

Review 6.  Comorbidities, Complications and Non-Pharmacologic Treatment in Idiopathic Pulmonary Fibrosis.

Authors:  Paloma Millan-Billi; Candela Serra; Ana Alonso Leon; Diego Castillo
Journal:  Med Sci (Basel)       Date:  2018-07-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.